NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase Model Leading a New Trend in Antibody Drug Development

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

PR Newswire associated2

PR Newswire associated3

Tags

NeoMab-Antibody

More Like This

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023